Milestone Scientific's Stock Highlights Etiome's New Chief Scientific Officer for Disease Detection Innovations

Etiome Appoints New Chief Scientific Officer to Drive Disease Detection Innovations

Etiome, a pioneering company in the biomedical field, recently appoints Jean Lachowicz, Ph.D., MBA, as its new Chief Scientific Officer. This strategic decision comes as Etiome seeks to enhance its Temporal Biodynamics™ platform, a groundbreaking initiative aimed at revolutionizing how diseases are detected and preempted. With a focus on developing Biostaged Medicines, the platform targets improved health outcomes for individuals at risk of chronic or progressive diseases. Lachowicz’s extensive background in drug discovery and development positions her uniquely to spearhead these innovations, which hold the potential to transform patient care.

Dr. Lachowicz brings nearly three decades of experience in research and development, having held significant roles in prominent organizations such as Schrodinger, Celgene, Merck, and Schering Plough. Her success in translating complex research into FDA-approved medicines across various therapeutic areas, including neurology, oncology, and immunology, underscores her capability to lead Etiome’s scientific endeavors. Avak Kahvejian, Etiome's Founding CEO, commends Lachowicz’s impressive track record and expresses confidence in her ability to propel the company’s mission forward. Lachowicz herself shares her enthusiasm for Etiome's vision, emphasizing the importance of understanding disease progression to enable earlier and more effective interventions.

The Temporal Biodynamics™ platform serves as a comprehensive framework for examining disease evolution, facilitating the identification of therapeutic targets and biomarkers essential for timely treatment. Founded in 2021, Etiome is committed to redefining disease detection and treatment methodologies, focusing on preemptive approaches that can halt or even reverse disease trajectories. As Lachowicz steps into her new role, the company aims to build a robust pipeline of Biostaged Medicines, marking a significant leap towards improving patient health outcomes. This appointment reflects Etiome's dedication to innovation in healthcare, establishing itself as a leader in the quest to enhance the quality of life for individuals facing chronic illnesses.

In parallel developments, BrioHealth Solutions celebrates a significant milestone in its INNOVATE Trial for the BrioVAD® System, enrolling its 100th patient. This Left Ventricular Assist Device (LVAD) is designed to improve care for advanced heart failure patients by augmenting blood flow and enhancing patient comfort. CEO Chen Chen, Ph.D., highlights the trial's importance in transforming the standard of care for those with advanced heart failure, showcasing the organization’s commitment to innovative healthcare solutions.

Both Etiome and BrioHealth Solutions illustrate a growing trend in the healthcare industry towards advancing technologies that prioritize early intervention and improved patient outcomes. As companies innovate and expand their research capabilities, the focus remains on enhancing treatment options and redefining the patient care landscape.